Magnetar Financial LLC
Institutional investor · Portfolio as of Q3 2020
Top Holdings640 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
WILLIS TOWERS WATSON PLC | 993,893 | $207.5M | 3.7% | $160.70 | +20.82% | 3 qtrssince 2020-Q1 | Decreased 0 |
CHURCHILL CAPITAL CORP IV | 18M | $180.2M | 3.2% | — | — | 1 qtr | New 84 |
VARIAN MED SYS INC | 953,718 | $164M | 2.9% | — | — | 1 qtr | New 79 |
MAXIM INTEGRATED PRODS INC | 2.4M | $160.9M | 2.8% | — | — | 1 qtr | New 79 |
LIVONGO HEALTH INC COM | 1.1M | $157M | 2.8% | — | — | 1 qtr | New 78 |
E TRADE FINANCIAL CORP | 2.9M | $146.4M | 2.6% | — | — | 3 qtrssince 2020-Q1 | Decreased 0 |
WRIGHT MED GROUP N V | 4.6M | $140.7M | 2.5% | — | — | 4 qtrssince 2019-Q4 | Increased 53 |
AMTD IDEA Group | 3.4M | $134.8M | 2.4% | $50.94 | -98.50% | 4 qtrssince 2019-Q4 | Decreased 0 |
ACACIA COMMUNICATIONS INC | 1.7M | $117.9M | 2.1% | — | — | 5 qtrssince 2019-Q3 | Increased 52 |
| 11M | $112.6M | 2.0% | — | — | — | New 69 | |
MOMENTA PHARMACEUTICALS INC | 1.9M | $102.1M | 1.8% | — | — | 1 qtr | New 68 |
IMMUNOMEDICS INC | 1.1M | $89.5M | 1.6% | — | — | 1 qtr | New 68 |
FLYING EAGLE ACQUISITION COR | 6.9M | $88.6M | 1.6% | — | — | 3 qtrssince 2020-Q1 | Unchanged 0 |
GRUBHUB INC | 1.2M | $86M | 1.5% | — | — | 3 qtrssince 2020-Q1 | Increased 55 |
BMC STK HLDGS INC | 2M | $85M | 1.5% | — | — | 1 qtr | New 68 |
ADVANCED DISP SVCS INC DEL | 2.6M | $77.9M | 1.4% | — | — | 6 qtrssince 2019-Q2 | Increased 48 |
FITBIT INC | 11M | $76.7M | 1.4% | — | — | 4 qtrssince 2019-Q4 | Increased 48 |
TIFFANY & CO NEW | 638,800 | $74M | 1.3% | — | — | 4 qtrssince 2019-Q4 | Increased 48 |
FTAC OLYMPUS ACQUISITION COR | 7.2M | $72M | 1.3% | — | — | 1 qtr | New 68 |
AIMMUNE THERAPEUTICS INC | 1.9M | $66.3M | 1.2% | — | — | 1 qtr | New 68 |
Magnetar Financial LLC manages $5.7B across 640 positions as of Q3 2020. Top holdings: WTW (3.7%), CCIV/U (3.2%), VAR (2.9%). Fund DNA: Diversified Scout. HoldingsIntel Rating: 3.5/5.0.
Active quarter - 373 new positions, 158 exits, 108 increased. Top move: CCIV/U (NEW, conviction 84). Portfolio: $5.7B across 640 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer